目的：本研究的目的在探討，新一代抗精神病藥物risperidone（每日2-16 mg）治療精神分裂症患者8週，對於活性症狀、負性症狀的臨床療效及安全性，以供日後臨床治療參考。方法：本研究為開放性臨床試驗，收集門診或住院病患診斷為精神分裂症患者，使用中文版活性及負性症狀評量表 (PANSS-CH)、臨床整體評量表 (CGI) 等評量表評估臨床療效，臨床療效之主要指標是以PANSS-CH總分之改善率　20%為反應良好與否之判準。以錐體外症狀評量表 (ESRS) 評估病患錐體外副作用，並且於每次訪視記錄病患副作用。結果：本試驗共收入25位病患。19 (76%) 位病患完成八週治療且完成評估，在CGI或PANSS-CH總分，於治療一週後評估就有統計上的差異；對於活性症狀 (PANSS-P)、負性症狀 (PANSS-N)、一般精神病理 (PANSS-G) 及攻擊危險度之補充項目 (PANSS-S)，各別於治療二週後評估，皆有統計上的差異；八週後PANSS的總分改善率為27.1%，19位病患最終平均使用劑量每日4.36±1.32 mg，11 (57.9%) 位病患為反應良好者。ESRS總分數基準6.89±14.85，八週後，為5.10±8.79，兩者無統計上的差異。治療最常見副作用包括：頭暈、失眠、口水增加等。結論：risperidone對於多數精神分裂症病患具有明顯療效，而且病患耐受性佳。

　　　　　Objectives: The purpose of this study is to evaluate the clinical improvement of positive and negative symptoms and safety of atypical antipsychotic agent,-risperidone (daily dose of 2-16 mg) in treating schizophrenic patients for eight weeks. Methods: The is an 8-week, open study. Subjects were recruited either out-patients or hospitalized patients. Chinese PANSS (PANSS-CH) and CGI (Clinical Global Impression) were used to assess therapeutic effects. Primary efficacy defined as　20% mean changes from the baseline of overall PANSS-CH scores. ESRS (Extrapyramidal Symptoms Rating Scale) was used as the marker to assess the side effects of extrapyramidal symptoms； any other side effects were recorded during each visit. Results: There were 25 subjects enrolled in this study; of which, 19 subjects (76%) had completed the 8-week treatment and all the evaluations; there was a statistically significant difference from the first-week data of CGI & PANSS-CH; there were statistically significant differences in the second-week data of subscales- positive (PANSS-P), negative (PANSS-N), general psychopathology (PANSS-G) and supplement items for the aggression risk profile (PANSS-S) of PANSS-CH. Average score of rate of improvement in using PANSS-CH, in a period of 8 weeks was 27.1%, of 19 subjects, 11 of them (57.9%) showed good response, the final average dose per day was 4.36±1.32 mg. The average score of ESRS was 6.89±14.85 and change to 5.10 ±8.79 after 8 weeks, it showed no statistically significant difference. The most common side effects are dizziness, insomnia, salivation increases etc. Conclusion: In this study, risperidone not only show prominent therapeutic effects for most patients but are also well tolerated.